Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study
ConclusionReslizumab is an effective and safe option for patients with severe eosinophilic asthma and a history of omalizumab failure.
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
More News: Allergy | Allergy & Immunology | Asthma | Corticosteroid Therapy | Study | Women | Xolair